US2012302739A1PendingUtilityA1

Biological products

61
Assignee: POPPLEWELL ANDREW GEORGEPriority: May 2, 2002Filed: Jul 13, 2012Published: Nov 29, 2012
Est. expiryMay 2, 2022(expired)· nominal 20-yr term from priority
C07K 2317/52C07K 2317/567A61K 2039/507C07K 16/464C07K 2317/41A61P 43/00C07K 2317/92C07K 16/3061C07K 2317/565C07K 2317/56C07K 16/2803C07K 2317/24A61K 2039/505A61K 39/39533C07K 16/2851C07K 2317/20C07K 2317/76C07K 2317/40C12N 15/11C07K 16/28C12Q 1/686G01N 33/567A61P 35/00G01N 33/53
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the clains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

Claims

exact text as granted — not AI-modified
1 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the light chain comprises residues 21 to 239 of the sequence given in SEQ ID NO:28. 
     
     
         2 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the light chain consists of residues 21 to 239 of the sequence given in SEQ ID NO:28. 
     
     
         3 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the heavy chain comprises residues 20 to 466 of the sequence given in SEQ ID NO:30. 
     
     
         4 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the heavy chain consists of residues 20 to 466 of the sequence given in SEQ ID NO:30. 
     
     
         5 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the heavy chain consists of residues 20 to 467 of the sequence given in SEQ ID NO:30. 
     
     
         6 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the light chain comprises an amino acid sequence resulting from the expression of SEQ ID NO:29 in a mammalian cell. 
     
     
         7 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the light chain consists of an amino acid sequence resulting from the expression of SEQ ID NO:29 in a mammalian cell. 
     
     
         8 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the heavy chain comprises an amino acid sequence resulting from the expression of SEQ ID NO:31 in a mammalian cell. 
     
     
         9 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the heavy chain consists of an amino acid sequence resulting from the expression of SEQ ID NO:31 in a mammalian cell. 
     
     
         10 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the light chain comprises residues 21 to 239 of the sequence given in SEQ ID NO:28 and the sequence of the heavy chain comprises residues 20 to 466 of the sequence given in SEQ ID NO:30. 
     
     
         11 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the light chain consists of residues 21 to 239 of the sequence given in SEQ ID NO:28 and the sequence of the heavy chain consists of residues 20 to 466 of the sequence given in SEQ ID NO:30. 
     
     
         12 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the sequence of the light chain consists of residues 21 to 239 of the sequence given in SEQ ID NO:28 and the sequence of the heavy chain consists of residues 20 to 467 of the sequence given in SEQ ID NO:30. 
     
     
         13 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the light chain comprises an amino acid sequence resulting from the expression of SEQ ID NO:29 and the heavy chain comprises an amino acid sequence resulting from the expression of SEQ ID NO:31 in a mammalian cell. 
     
     
         14 . An antibody molecule having specificity for human CD22, comprising a light chain and a heavy chain, wherein the light chain consists of an amino acid sequence resulting from the expression of SEQ ID NO:29 and the heavy chain consists of an amino acid sequence resulting from the expression of SEQ ID NO:31 in a mammalian cell.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.